NOT FDA-APPROVED

KPV (Lys-Pro-Val)

Almost always blended · the K in KLOW

Most often used as part of the KLOW blend alongside GHK-Cu, BPC-157, and TB-500. Three amino acids, one job: damping inflammation. A tiny fragment of the body's own anti-inflammatory hormone, with most of the published research in animal models of gut and skin inflammation.

The 30-second read

KPV is a three-amino-acid peptide (lysine-proline-valine), the C-terminal "tail" of alpha-MSH, the body's natural anti-inflammatory hormone. The pitch: it carries much of alpha-MSH's anti-inflammatory effect without the pigmentation and other systemic effects. Animal and cell-culture research on KPV is consistent, it reduces inflammatory signaling (NF-κB pathway) in gut and skin models. Human clinical trials don't exist yet for the tripeptide specifically. It's not FDA-approved. It shows up most often in research-peptide circles for IBS/IBD-type gut symptoms, eczema/psoriasis-type skin conditions, and as a component of the KLOW skin blend. The basic biology is interesting; the human evidence is sparse.

Why this peptide is on people's radar

KPV is unusual in the peptide world because it's so small, just three amino acids, that it barely meets the definition of a peptide at all. But size doesn't mean inactive. The KPV sequence is the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a small hormone that has well-documented anti-inflammatory effects in the body. Researchers studying alpha-MSH found that the C-terminal tail (KPV alone) preserves much of the anti-inflammatory activity without the pigmentation effects of the full hormone.

That makes KPV interesting for inflammatory conditions where you want the anti-inflammatory effect but not the systemic activity of full alpha-MSH. Researchers have studied it in gut-inflammation models (IBD, ulcerative colitis), skin-inflammation models (eczema, psoriasis), and broader anti-inflammatory contexts. The animal evidence is reasonably consistent. The human clinical-trial evidence is essentially absent for the tripeptide specifically.

In the research-peptide community, KPV gets discussed for chronic gut inflammation and skin conditions, and it's a component of the KLOW skin blend (KPV + GLOW: BPC-157 + TB-500 + GHK-Cu). The mechanism. NF-κB pathway inhibition without immunosuppression, is the kind of thing that makes biology-minded readers pay attention.

What people are usually trying to do with it

People exploring KPV are usually focused on:

  • Calming gut inflammation (IBS-type symptoms, IBD-style flares, persistent gut sensitivity)
  • Reducing skin inflammation (eczema, psoriasis-type conditions, contact dermatitis)
  • Supporting healing of inflamed tissue more broadly
  • Adding an anti-inflammatory peptide to a research stack, often alongside BPC-157
  • Trying an option that's not a steroid or a systemic immunosuppressant

What the science actually shows

The biology is well-documented; the human side is missing. Plain-English summary:

Anti-inflammatory mechanism (well-characterized)

KPV inhibits NF-κB signaling in cell-culture and animal studies, reducing pro-inflammatory cytokine production (IL-6, TNF-α, IL-8) without broadly suppressing the immune system. The mechanistic picture is consistent.1

Gut inflammation models

Animal studies in colitis and IBD models report reductions in inflammation, improved mucosal healing, and lower disease severity scores following KPV administration (oral or rectal).2

Skin inflammation models

Topical and animal studies in eczema, psoriasis, and dermatitis models show reductions in inflammation and improved skin barrier markers.3

Wound healing

Some preclinical work has examined KPV in wound-healing models, with reports of faster epithelialization and reduced inflammatory markers in healing tissue.4

What hasn't been demonstrated

Human clinical trials of KPV for any indication. As of 2026, no Phase 2 or Phase 3 trials are registered. Long-term safety data in humans does not exist. The leap from animal models to human clinical use rests on the broader alpha-MSH research and on KPV's structural relationship to that family.

The honest read

What's solid:

KPV's mechanism. NF-κB pathway inhibition that reduces inflammation without suppressing immune surveillance, is well-characterized at the molecular level. The animal evidence in gut and skin inflammation models is consistent. The structural connection to alpha-MSH is meaningful biology.

What's still unproven:

Effectively all of the human use case. There are no Phase 2 or Phase 3 trials of KPV. The crossover from "works in mouse colitis" to "works in human Crohn's disease" is a big inferential leap that hasn't been tested. Long-term safety in healthy adults is uncharacterized. Optimal dose and route are not established.

What's hyped beyond the evidence:

Treating KPV as an established treatment for IBD, eczema, or any specific condition. The evidence is preclinical. Anyone with a serious gut or skin condition has FDA-approved options that are clinically validated; KPV has not been put through that process. Claims about "natural anti-inflammatory" can also overstate it. KPV is a synthetic peptide derived from a hormone, not a supplement.

Things to know if you're looking into it

  • How it's used in research: typically a subcutaneous injection or oral capsule. Some research-community protocols use oral administration for gut indications and injection for systemic anti-inflammatory use.
  • Often blended: KPV is the K in the KLOW blend (KPV + GLOW: BPC-157 + TB-500 + GHK-Cu), a popular research-peptide skin formulation. KLOW blend explainer →
  • Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
  • Reported tolerability: in research-community use, side effects are uncommon and mostly mild. Long-term safety in healthy adults is not characterized.
  • Not a substitute for evaluation: serious gut symptoms (persistent diarrhea, blood in stool, severe pain, weight loss) need proper diagnosis. Skin conditions that aren't responding to first-line care need a dermatologist. KPV does not replace those evaluations.
  • Healthcare provider involvement: recommended, especially in combination with other peptides or for chronic conditions.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

Does KPV work for gut inflammation in humans?

The animal data suggests yes. There are no human trials confirming it. People with diagnosed IBD have FDA-approved treatments that have been tested in humans; KPV would be off-label and outside that evidence base.

How is it different from BPC-157?

Different mechanism. BPC-157 promotes tissue repair through angiogenesis and growth-factor pathways. KPV reduces inflammation through NF-κB inhibition. They're sometimes combined because they target different parts of the gut-healing picture.

Can you take it orally?

For gut indications, oral administration is sometimes used because the peptide can act locally on gut tissue without needing systemic absorption. Whether oral KPV reaches systemic circulation in any useful way isn't clearly established.

Is it FDA-approved?

No. Not approved for any indication.

Are there side effects?

Reported side effects in animal studies and community use are uncommon and mostly mild, occasional injection-site reactions for parenteral use, and mild GI complaints with oral use. Long-term safety isn't characterized.

What's the KLOW blend?

A four-peptide skin and tissue blend: KPV + GLOW (BPC-157 + TB-500 + GHK-Cu). The KPV component adds the anti-inflammatory mechanism to the GLOW skin-repair formulation. No human trials of the combination exist. Read the KLOW explainer →

Why is it on the radar if it's so small?

Small peptides can be biologically active. KPV preserves much of alpha-MSH's anti-inflammatory effect in a fraction of the size, which is unusual and is what made it interesting to researchers initially.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. No Phase 2 or Phase 3 clinical trials of KPV are registered on ClinicalTrials.gov as of this date. Status updates land here when they happen.

Want to go deeper? Mechanism, NF-κB pathway detail, dosing, side effects, and references. Click to expand.

Background and discovery

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), the sequence Lys-Pro-Val (lysine-proline-valine, amino acids 11-13 of alpha-MSH). Researchers studying alpha-MSH's anti-inflammatory effects in the 1990s and 2000s discovered that the KPV C-terminal fragment retained much of the anti-inflammatory activity without the pigmentation and other systemic melanocortin effects. That made KPV an interesting starting point for inflammation-focused research without the off-target effects of full alpha-MSH.

Mechanism of action

NF-κB pathway inhibition

The central mechanism. KPV interferes with the NF-κB inflammatory signaling pathway, reducing transcription of pro-inflammatory cytokines (IL-6, TNF-α, IL-8) and inflammatory mediators in cells exposed to inflammatory stimuli.

Anti-inflammatory without immunosuppression

Unlike steroids or systemic immunosuppressants, KPV's effect on NF-κB is selective enough that it does not broadly suppress the immune system. Antimicrobial peptide expression and immune cell function appear preserved or enhanced in some studies, important context for gut inflammation, where maintaining immune surveillance matters.

Local versus systemic activity

KPV can be given orally for local gut effects (the peptide acts on intestinal epithelium directly) or via injection for more systemic anti-inflammatory effects. The mechanism is the same; the route changes which tissues see meaningful exposure.

Direct anti-microbial activity

Some studies suggest KPV has direct antimicrobial activity against certain bacterial species, including some clinically relevant strains, in addition to its anti-inflammatory effect.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Subcutaneous (research range): 200 to 500 mcg per day, often split as twice-daily dosing.

Oral (gut-focused research range): 500 mcg to 1 mg per day in capsule form, often taken on an empty stomach.

Topical (skin-focused research): as part of formulated topical products, typically at low concentrations (similar to GHK-Cu cosmetic ranges).

Treatment duration: typical research-community cycles are 4 to 8 weeks. Long-term continuous use has not been formally characterized.

Side effects and safety profile

Reported in preclinical research and research-community use:

  • Mild injection-site reactions (uncommon)
  • Mild GI symptoms with oral use (uncommon)
  • No significant systemic effects reported in animal toxicology

Long-term safety in healthy adults has not been formally characterized. Theoretical considerations are minimal. KPV's small size and selective NF-κB mechanism limit the routes through which serious adverse effects might occur, but absence of evidence isn't evidence of absence.

References

  1. Brzoska T, Luger TA, Maaser C, et al. (2008). "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocr Rev, 29(5), 581–602. PubMed
  2. Kannengiesser K, Maaser C, Heidemann J, et al. (2008). "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis, 14(3), 324–331. PubMed
  3. Luger TA, Brzoska T. (2007). "Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Ann Rheum Dis, 66(suppl 3), iii52–iii55. PubMed
  4. Bonfiglio V, Camillieri G, Avitabile T, et al. (2006). "Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing." Peptides, 27(1), 41–46. PubMed
  5. Hiltz ME, Lipton JM. (1990). "Anti-inflammatory activity of α-MSH(11-13)." Peptides, 11(5), 979–982. PubMed
For educational and research purposes only. This is not medical advice. KPV is not FDA-approved. Serious gut or skin conditions should be evaluated and treated using FDA-approved options under clinical supervision. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.